TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations

Authors

Xiwei Chen (ORCID: https://orcid.org/0000-0003-1868-8387)
T. Newsom-Davis
Rebecca S. Heist (ORCID: https://orcid.org/0000-0002-7397-2009)
Marta Stachowiak
Alessandra Forcina (ORCID: https://orcid.org/0009-0003-3192-4118)
Barbara Melosky (ORCID: https://orcid.org/0000-0003-2865-659X)
Giulia Pasello (ORCID: https://orcid.org/0000-0002-8741-6038)
Shun Lu (ORCID: https://orcid.org/0000-0002-1833-475X)
Pavlo Lyfar
Suresh S. Ramalingam

Institutions

BC Cancer Agency (CA)
Emory University (US)
Massachusetts General Hospital (US)
Fudan University Shanghai Cancer Center (CN)
Piedmont Cancer Institute (US)
Radiation Oncology Institute (US)
Istituto Oncologico Veneto (IT)
Shanghai Cancer Institute (CN)
AstraZeneca (Switzerland) (CH)
Chelsea and Westminster Hospital (GB)
AstraZeneca (Poland) (PL)

Publication Details

Journal: Frontiers in Oncology
Published: 2026-01-26
DOI: https://doi.org/10.3389/fonc.2025.1721624
Primary Topic: Cancer Immunotherapy and Biomarkers
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Sanofi
Gilead Sciences
Regeneron Pharmaceuticals
Novocure
Mirati Therapeutics
BeiGene
Innovent Biologics
Yuhan
EQRx
Daiichi Sankyo Europe

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations

Xiwei Chen, T. Newsom-Davis, Rebecca S. Heist, Marta Stachowiak et al.

Jan 26, 2026

Frontiers in Oncology

Cancer Immunotherapy and Biomarkers

article

TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations

Xiwei Chen, T. Newsom-Davis, Rebecca S. Heist, Marta Stachowiak, Alessandra Forcina, Barbara Melosky, Giulia Pasello, Shun Lu, Pavlo Lyfar, Suresh S. Ramalingam

January 26, 2026article en

Abstract

No abstract available for this paper.

Frontiers in OncologyVol. 15

BC Cancer Agency (CA), Emory University (US), Massachusetts General Hospital (US), Fudan University Shanghai Cancer Center (CN), Piedmont Cancer Institute (US), Radiation Oncology Institute (US), Istituto Oncologico Veneto (IT), Shanghai Cancer Institute (CN), AstraZeneca (Switzerland) (CH), Chelsea and Westminster Hospital (GB), AstraZeneca (Poland) (PL)

Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Regeneron Pharmaceuticals, Novocure, Mirati Therapeutics, BeiGene, Innovent Biologics, Yuhan, EQRx, Daiichi Sankyo Europe

Good health and well-being

Openalex Percentile: Top 78%

Cancer Immunotherapy and Biomarkers

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.